Clinical trial
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor…
NCT00141297 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00141297 |
|---|---|
| Title | A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer |
| Official title | A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Lymphoma, Non-Hodgkin |
| Intervention type | Drug |
| Interventions | PD-0332991 |
| Enrollment | 74 |
| Start date | Sep 1, 2004 |
| Primary completion | Jul 1, 2008 |
| Completion | Dec 1, 2014 |
| First posted | Sep 1, 2005 |
| Last update posted | Jan 5, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: